Risk factors
Curanex Pharmaceuticals (CURX) risk factors
Item 1A of every Curanex Pharmaceuticals Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors39 risks
Curanex Pharmaceuticals focuses entirely on developing its lead botanical drug candidate, Phyto-N, after halting health product sales in 2023. The company faces a Nasdaq minimum bid price deficiency, key patent expirations, and heavy insider control by founders.
Filed Mar 30, 2026